Mineralys Therapeutics, Inc. (MLYS) shareholders
Close on Nov 17, 2026Market cap $1.28BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Catalys Pacific Fund, LP Joint filing with Catalys Pacific Fund GP, LP (10.10%), Catalys Pacific, LLC (10.10%) and 1 more | 8,002,738 | 10.10% | 13G (passive) amendment | Dec 31, 2025 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 7,796,433 | 9.90% | 13D (active) amendment | Sep 4, 2025 |
| Srinivas Akkaraju Joint filing with Samsara BioCapital, L.P. (7.30%), Samsara BioCapital GP, LLC (7.30%) | 6,346,194 | 8.20% | 13D (active) amendment | Sep 4, 2025 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (9.90%), Rajeev Shah (9.90%) and 1 more | 6,287,597 | 9.90% | 13D (active) amendment | Mar 13, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (6.30%) | 5,017,509 | 6.30% | 13G (passive) | Dec 31, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (5.10%) | 4,461,689 | 5.10% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 4,113,657 | 5.20% | 13G (passive) | Dec 31, 2025 |
| TCG Crossover GP II, LLC Joint filing with TCG Crossover Fund II, L.P. (5.00%), Chen Yu (5.00%) | 2,470,265 | 5.00% | 13G (passive) amendment | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MLYS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Catalys Pacific, LLC | 7,903,838 | 8.94% | $213.25M | – | 92.94% |
| Ra Capital Management, L.P. | 7,692,750 | 8.70% | $207.55M | – | 1.80% |
| BlackRock, Inc. | 5,887,038 | 6.66% | $158.83M | +1,405,456 | 0.00% |
| Samsara BioCapital, LLC | 5,871,018 | 6.64% | $158.40M | – | 13.01% |
| FMR LLC | 4,511,689 | 5.10% | $121.73M | −349,415 | 0.01% |
| State Street Corp | 4,141,636 | 4.68% | $111.74M | +1,205,696 | 0.00% |
| Deerfield Management Company, L.P. (Series C) | 3,958,000 | 4.48% | $106.79M | New | 1.11% |
| Vanguard Capital Management LLC | 2,756,770 | 3.12% | $74.38M | +302,407 | 0.00% |
| Laurion Capital Management LP | 2,506,152 | 2.83% | $67.62M | +274,112 | 1.73% |
| Price T Rowe Associates Inc /Md/ | 2,262,476 | 2.56% | $61.04M | +919,163 | 0.01% |
| Orbimed Advisors LLC | 2,110,300 | 2.39% | $56.94M | +57,400 | 1.05% |
| Capital World Investors | 1,997,607 | 2.26% | $53.90M | +1,599,428 | 0.01% |
| Armistice Capital, LLC | 1,736,000 | 1.96% | $46.84M | +560,000 | 0.57% |
| Troluce Capital Advisors LLC | 1,728,753 | 1.96% | $46.64M | +1,073,753 | 4.80% |
| Nantahala Capital Management, LLC | 1,640,962 | 1.86% | $44.27M | +745,481 | 0.74% |
| Franklin Resources Inc | 1,635,520 | 1.85% | $44.13M | −149,142 | 0.01% |
| Andera Partners | 1,591,917 | 1.80% | $42.95M | – | 20.80% |
| Geode Capital Management, LLC | 1,584,326 | 1.79% | $42.75M | +283,191 | 0.00% |
| Sr One Capital Management, LP | 1,563,966 | 1.77% | $42.20M | – | 4.06% |
| Bank Of America Corp /De/ | 1,505,547 | 1.70% | $40.62M | +405,175 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 226 | 100M | 100.0% | 36 / 90 | 65 / 22 | 26M | 16M |
| Q1 2026 | 215 | 91M | 100.0% | 33 / 98 | 52 / 38 | 18M | 12M |
| Q4 2025 | 223 | 88M | 100.0% | 52 / 82 | 72 / 20 | 23M | 14M |
| Q3 2025 | 193 | 80M | 89.9% | 43 / 68 | 63 / 15 | 23M | 10M |
| Q2 2025 | 165 | 66M | 74.3% | 42 / 75 | 30 / 24 | 12M | 7M |
| Q1 2025 | 148 | 61M | 68.8% | 54 / 53 | 26 / 13 | 20M | 6M |
| Q4 2024 | 108 | 46M | 52.6% | 16 / 44 | 17 / 14 | 4M | 2M |
| Q3 2024 | 106 | 44M | 50.2% | 19 / 36 | 23 / 6 | 5M | 3M |
| Q2 2024 | 94 | 45M | 50.6% | 14 / 48 | 13 / 12 | 6M | 4M |
| Q1 2024 | 92 | 43M | 48.6% | 17 / 25 | 33 / 12 | 11M | 3M |
| Q4 2023 | 87 | 35M | 39.9% | 23 / 36 | 14 / 12 | 13M | 4M |
| Q3 2023 | 77 | 27M | 30.0% | 22 / 28 | 11 / 13 | 4M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
228 funds held MLYS in Q2 2026, 35% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MLYS | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,820,768 | 3.19% | $76.10M | 0.71% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,968,124 | 2.23% | $53.10M | 0.00% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 1,652,360 | 1.87% | $44.58M | 0.05% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,495,279 | 1.69% | $40.34M | 0.05% | Jun 30, 2026 |
| Select Health Care Portfolio | 1,180,000 | 1.33% | $37.17M | 0.64% | May 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 828,597 | 0.94% | $22.36M | 0.15% | Jun 30, 2026 |
| Small Cap Growth Fund | 792,377 | 0.90% | $20.22M | 0.36% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 728,429 | 0.82% | $19.65M | 0.02% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 630,000 | 0.71% | $19.85M | 0.01% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 627,892 | 0.71% | $16.02M | 0.05% | Jul 31, 2026 |
| Fidelity Advisor Health Care Fund | 600,000 | 0.68% | $15.31M | 0.49% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 538,986 | 0.61% | $14.54M | 0.09% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 538,629 | 0.61% | $14.53M | 0.15% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 533,511 | 0.60% | $13.62M | 1.18% | Jul 31, 2026 |
| PGIM Jennison Health Sciences Fund | 459,547 | 0.52% | $14.48M | 1.04% | May 29, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jon Congleton | Chief Executive Officer, Director | 528,621 | 0.60% | Oct 2, 2026 |
| Eric Warren | Chief Commercial Officer | 45,838 | 0.05% | Sep 22, 2026 |
| David Malcom Rodman | Chief Medical Officer | 51,384 | 0.06% | Aug 12, 2026 |
| James J. Ferguson III | Chief Medical Officer | 102,400 | 0.12% | Aug 12, 2026 |
| Adam Scott Levy | CFO and Secretary | 48,538 | 0.05% | Feb 20, 2026 |
| Lonnel Coats | Director | 12,400 | 0.01% | Oct 20, 2026 |
| Kristine Peterson | Director | 12,400 | 0.01% | Oct 20, 2026 |
| Brian Taylor Slingsby | Director | 7,811,918 | 8.84% | Sep 24, 2026 |
| Daphne Karydas | Director | 6,200 | 0.01% | Sep 17, 2026 |
| Capital Healthcare Fund LP RA | Director | 1,873,429 | 2.12% | Mar 31, 2026 |
| Rajeev M. Shah | Director | 5,825,521 | 6.59% | Mar 31, 2026 |
| RA Capital Nexus Fund III, L.P. | Director | 4,280,051 | 4.84% | Mar 31, 2026 |
| Peter Kolchinsky | Director | – | – | Mar 31, 2026 |
| Ra Capital Management, L.P. | Director | 5,456,521 | 6.17% | Mar 31, 2026 |
| Glenn Sblendorio | Director | 6,200 | 0.01% | Feb 20, 2026 |
| Derek DiRocco | Director | 6,200 | 0.01% | Feb 20, 2026 |
| Alexander M. Gold | Director | 6,200 | 0.01% | Feb 20, 2026 |
| Srinivas Akkaraju | Director, 10% owner | 5,877,218 | 6.65% | Feb 20, 2026 |
| Catalys Pacific Fund, LP | 10% owner | 7,903,838 | 8.94% | Nov 21, 2025 |
| Samsara BioCapital GP, LLC | 10% owner | – | – | Mar 17, 2025 |
| Samsara BioCapital, L.P. | 10% owner | 5,674,916 | 6.42% | Mar 17, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Lonnel Coats Director | Oct 19, 2026 | Award | +12,400 | – | – | 12,400 |
| Kristine Peterson Director | Oct 19, 2026 | Award | +12,400 | – | – | 12,400 |
| Jon Congleton Chief Executive Officer, Director | Sep 30, 2026 | Sale(10b5-1 plan) | −75,000 | $25.46 | $1.91M | 528,621 |
| Brian Taylor Slingsby Director | Sep 22, 2026 | Sale | −104,320 | $28.81 | $3.01M | 7,805,718 |
| Eric Warren Chief Commercial Officer | Sep 21, 2026 | Option exercise | +7,438 | $13.24 | $98.48K | 45,838 |
| Eric Warren Chief Commercial Officer | Sep 21, 2026 | Sale(10b5-1 plan) | −7,438 | $28.12 | $209.16K | 38,400 |
| Daphne Karydas Director | Sep 15, 2026 | Sale(10b5-1 plan) | −3,000 | $28.58 | $85.74K | 6,200 |
| Daphne Karydas Director | Sep 15, 2026 | Option exercise | +3,000 | $12.02 | $36.06K | 9,200 |
| Eric Warren Chief Commercial Officer | Aug 21, 2026 | Sale(10b5-1 plan) | −7,437 | $25.98 | $193.21K | 38,400 |
| Eric Warren Chief Commercial Officer | Aug 21, 2026 | Option exercise | +7,437 | $13.24 | $98.47K | 45,837 |
| James J. Ferguson III Chief Medical Officer | Aug 10, 2026 | Award | +102,400 | – | – | 102,400 |
| David Malcom Rodman Chief Medical Officer | Aug 10, 2026 | Sale(10b5-1 plan) | −2,170 | $27.09 | $58.79K | 51,384 |
| David Malcom Rodman Chief Medical Officer | Aug 10, 2026 | Option exercise | +2,170 | $16.00 | $34.72K | 53,554 |
| Eric Warren Chief Commercial Officer | Jul 21, 2026 | Option exercise | +7,438 | $13.24 | $98.48K | 45,838 |
| Eric Warren Chief Commercial Officer | Jul 21, 2026 | Sale(10b5-1 plan) | −7,438 | $26.87 | $199.86K | 38,400 |
| David Malcom Rodman Chief Medical Officer | Jul 17, 2026 | Sale(10b5-1 plan) | −416 | $26.53 | $11.04K | 51,384 |
| David Malcom Rodman Chief Medical Officer | Jul 17, 2026 | Option exercise | +416 | $15.44 | $6.42K | 51,800 |
| David Malcom Rodman Chief Medical Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −6,349 | $26.61 | $168.95K | 51,384 |
| David Malcom Rodman Chief Medical Officer | Jul 13, 2026 | Option exercise | +6,349 | $1.08 | $6.86K | 71,791 |
| David Malcom Rodman Chief Medical Officer | Jul 13, 2026 | Option exercise | +3,542 | $10.20 | $36.13K | 61,275 |
| David Malcom Rodman Chief Medical Officer | Jul 13, 2026 | Sale(10b5-1 plan) | −14,058 | $27.58 | $387.72K | 57,733 |
| David Malcom Rodman Chief Medical Officer | Jul 13, 2026 | Option exercise | +4,167 | $14.25 | $59.38K | 65,442 |
| Jon Congleton Chief Executive Officer, Director | Jul 13, 2026 | Sale(10b5-1 plan) | −10,700 | $27.24 | $291.47K | 603,621 |
| David Malcom Rodman Chief Medical Officer | Jul 9, 2026 | Sale(10b5-1 plan) | −2,171 | $30.30 | $65.78K | 57,733 |
| David Malcom Rodman Chief Medical Officer | Jul 9, 2026 | Option exercise | +2,171 | $16.00 | $34.74K | 59,904 |
| Jon Congleton Chief Executive Officer, Director | Jun 30, 2026 | Sale(10b5-1 plan) | −58,000 | $25.94 | $1.50M | 631,321 |
| Jon Congleton Chief Executive Officer, Director | Jun 30, 2026 | Sale(10b5-1 plan) | −17,000 | $26.82 | $455.94K | 614,321 |
| Eric Warren Chief Commercial Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −104,124 | $25.90 | $2.70M | 38,400 |
| Eric Warren Chief Commercial Officer | Jun 26, 2026 | Option exercise | +104,124 | $13.24 | $1.38M | 142,524 |
| David Malcom Rodman Chief Medical Officer | Jun 17, 2026 | Option exercise | +4,167 | $14.25 | $59.38K | 61,262 |
| David Malcom Rodman Chief Medical Officer | Jun 17, 2026 | Sale(10b5-1 plan) | −4,584 | $25.00 | $114.60K | 57,095 |
| David Malcom Rodman Chief Medical Officer | Jun 17, 2026 | Option exercise | +417 | $15.44 | $6.44K | 61,679 |
| Daphne Karydas Director | Jun 17, 2026 | Sale(10b5-1 plan) | −3,000 | $25.00 | $75.00K | 6,200 |
| Daphne Karydas Director | Jun 17, 2026 | Option exercise | +3,000 | $12.02 | $36.06K | 9,200 |
| David Malcom Rodman Chief Medical Officer | Jun 15, 2026 | Sale(10b5-1 plan) | −9,890 | $23.81 | $235.48K | 57,095 |
| David Malcom Rodman Chief Medical Officer | Jun 15, 2026 | Option exercise | +3,542 | $10.20 | $36.13K | 66,985 |
| David Malcom Rodman Chief Medical Officer | Jun 12, 2026 | Option exercise | +6,349 | $1.08 | $6.86K | 69,792 |
| David Malcom Rodman Chief Medical Officer | Jun 12, 2026 | Sale(10b5-1 plan) | −6,349 | $23.93 | $151.93K | 63,443 |
| David Malcom Rodman Chief Medical Officer | Jun 10, 2026 | Option exercise | +2,170 | $16.00 | $34.72K | 65,613 |
| David Malcom Rodman Chief Medical Officer | Jun 10, 2026 | Sale(10b5-1 plan) | −2,170 | $25.00 | $54.25K | 63,443 |
| David Malcom Rodman Chief Medical Officer | May 18, 2026 | Sale(10b5-1 plan) | −417 | $27.55 | $11.49K | 63,443 |
| David Malcom Rodman Chief Medical Officer | May 18, 2026 | Option exercise | +417 | $15.44 | $6.44K | 63,860 |
| David Malcom Rodman Chief Medical Officer | May 13, 2026 | Sale(10b5-1 plan) | −14,056 | $28.58 | $401.72K | 63,443 |
| David Malcom Rodman Chief Medical Officer | May 13, 2026 | Option exercise | +3,541 | $10.20 | $36.12K | 73,333 |
| David Malcom Rodman Chief Medical Officer | May 13, 2026 | Option exercise | +4,166 | $14.25 | $59.37K | 77,499 |
| David Malcom Rodman Chief Medical Officer | May 12, 2026 | Sale(10b5-1 plan) | −6,348 | $29.36 | $186.38K | 69,792 |
| David Malcom Rodman Chief Medical Officer | May 12, 2026 | Option exercise | +6,348 | $1.08 | $6.86K | 76,140 |
| David Malcom Rodman Chief Medical Officer | May 11, 2026 | Option exercise | +2,171 | $16.00 | $34.74K | 71,963 |
| David Malcom Rodman Chief Medical Officer | May 11, 2026 | Sale(10b5-1 plan) | −2,171 | $29.71 | $64.50K | 69,792 |
| David Malcom Rodman Chief Medical Officer | Apr 17, 2026 | Option exercise | +416 | $15.44 | $6.42K | 70,208 |
| David Malcom Rodman Chief Medical Officer | Apr 17, 2026 | Sale(10b5-1 plan) | −416 | $31.33 | $13.03K | 69,792 |
| David Malcom Rodman Chief Medical Officer | Apr 15, 2026 | Sale(10b5-1 plan) | −6,348 | $27.66 | $175.59K | 69,792 |
| Jon Congleton Chief Executive Officer, Director | Apr 13, 2026 | Sale(10b5-1 plan) | −15,730 | $26.83 | $422.04K | 689,321 |
| David Malcom Rodman Chief Medical Officer | Apr 13, 2026 | Option exercise | +4,167 | $14.25 | $59.38K | 90,198 |
| David Malcom Rodman Chief Medical Officer | Apr 13, 2026 | Sale(10b5-1 plan) | −14,058 | $26.54 | $373.10K | 76,140 |
| David Malcom Rodman Chief Medical Officer | Apr 13, 2026 | Option exercise | +6,349 | $1.08 | $6.86K | 82,489 |
| David Malcom Rodman Chief Medical Officer | Apr 13, 2026 | Option exercise | +3,542 | $10.20 | $36.13K | 86,031 |
| David Malcom Rodman Chief Medical Officer | Apr 9, 2026 | Sale(10b5-1 plan) | −2,170 | $27.38 | $59.41K | 76,140 |
| David Malcom Rodman Chief Medical Officer | Apr 9, 2026 | Option exercise | +2,170 | $16.00 | $34.72K | 78,310 |
| Daphne Karydas Director | Mar 31, 2026 | Sale(10b5-1 plan) | −3,000 | $25.00 | $75.00K | 6,200 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Mineralys Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 28,905 shares on Sep 3, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| David Malcom Rodman Officer | Oct 13, 2026 | 3,542 | $78.07K | Oct 13, 2026 | Exercise of employee stock options |
| Jon Congleton Officer, Director | Sep 30, 2026 | 75,000 | $1.91M | Sep 30, 2026 | Vesting of Restricted Stock Unit Awards |
| Catalys Pacific Fund, LP Director | Sep 22, 2026 | 104,320 | $3.01M | Sep 22, 2026 | Private Acquisition from Issuer/Affiliate |
| Eric Warren Officer | Sep 21, 2026 | 7,438 | $209.14K | Sep 21, 2026 | Exercise of employee stock options |
| David Malcom Rodman Officer | Sep 17, 2026 | 417 | $11.66K | Sep 17, 2026 | Exercise of employee stock options |
| Daphne Karydas Officer | Sep 15, 2026 | 3,000 | $85.74K | Sep 15, 2026 | Exercise of employee stock options |
| David Malcom Rodman Officer | Sep 14, 2026 | 7,709 | $216.93K | Sep 14, 2026 | Exercise of employee stock options |
| David Malcom Rodman Officer | Sep 9, 2026 | 2,171 | $67.02K | Sep 9, 2026 | Exercise of employee stock options |
| Eric Warren Officer | Aug 21, 2026 | 7,437 | $193.19K | Aug 21, 2026 | Exercise of employee stock options |
| David Malcom Rodman Officer | Aug 17, 2026 | 417 | $10.62K | Aug 17, 2026 | Exercise of employee stock options |
| David Malcom Rodman Officer | Aug 13, 2026 | 14,056 | $372.19K | Aug 13, 2026 | Exercise of employee stock options |
| David Malcom Rodman Officer | Aug 10, 2026 | 2,170 | $58.79K | Aug 10, 2026 | Exercise of employee stock options |
| Eric Warren Officer | Jul 21, 2026 | 7,438 | $199.88K | Jul 21, 2026 | Exercise of employee stock options |
| David Malcom Rodman Officer | Jul 17, 2026 | 416 | $11.02K | Jul 17, 2026 | Exercise of employee stock options |
| David Malcom Rodman Officer | Jul 15, 2026 | 6,349 | $168.95K | Jul 15, 2026 | Exercise of employee stock options |
See a number that looks wrong?